Seronegative spondyloarthropathy-associated inflammatory bowel disease

Table 4 Demographic, clinical, laboratory, medication, course, and outcome profiles in 4 ankylosing spondylitis-associated inflammatory bowel disease patients from 2017 January to 2021 December[30]

No.	Age in yr and sex	1AS period in yr	Affected joints	Other EA	3BASDAI/2AS medication	HLA-B27/3ESR	IBD clinical manifestation	IBD entity/6severity	4IBD medication	Disease course, under ADA 40 mg q2w SCI	Final outcome
1	42, F	12	SI, spine, hip	Uveitis	7.6/NSAIDs	Positive/38	Rectal bleeding, BWL, anemia	UP/ moderate, MS 9	CS, mSAZ, ADA 40 mg q2w	No IBD relapse for 4.3 yr	AS in low activity with BASDAI 2.0-2.5, IBD in remission, MS 0
2	35, M	15	SI, spine, hip	Uveitis	8.8/NSAIDs, SAZ	Positive/80	Bloody diarrhea, BWL, fever, anemia	UC/severe, MS 12	CS, mSAZ, ADA 40 mg q4 to q2w	No IBD relapse for 4.8 yr	AS in low activity with BASDAI 2.5-3.0, IBD in remission, MS 1
3	45, M	14	SI, spine, hip	Nil	8.4/NSAIDs, SAZ	Positive/42	Bloody diarrhea, BWL, anemia, 5colon perforation	UC/severe, MS 11	CS, SAZ, ADA 40 mg q2w	No IBD relapse for 5.8 yr	AS in low activity with BASDAI 2.5-3.0, IBD in remission, MS 2
4	45, F	25	SI, spine, shoulder hip	Nil	8.1/NSAIDs, SAZ, MTX	Positive/35	Bloody diarrhea, BWL, anemia	UC/severe, MS 11	CS, SAZ, ADA 40 mg q4 to q2w	No IBD relapse for 5.3 yr	AS in low activity with BASDAI 2.5-3.0, IBD in remission, MS 1

¹AS duration before the inflammatory bowel disease (IBD) development.

²Methotrexate 15 mg per wk, salazopyrin 2 to 3 g/d, nonsteroidal anti-inflammatory drugs only with Coxibs after IBD diagnosis.

³At disease onset of IBD.

⁴High-dose corticosteroids (CS, 1-2 mg/kg/d prednisolone equivalent doses) for acute ulcerative colitis (UC), topical CS for active ulcerative proctitis, low-dose CS for UC maintenance.

⁵Perforation at the splenic flexure, under double barrel colostomy and abdominal abscess drainage.

⁶MS: Mayo score, 11-12 severe, 6-10 moderate, 3-5 mild, 0-2 remission.

Age at diagnosis of inflammatory bowel disease. ADA: Adalimumab; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BWL: Body weight loss; CS: Corticosteroids; ESR: Erythrocyte sedimentation rate (normal value ≤ 15 mm/h); F: Female; IBD: Inflammatory bowel disease; M: Male; mSAZ: Mesalazine; MTX: Methotrexate; No.: Number; NSAIDs: Nonsteroidal anti-inflammatory drugs; q2w: Every 2 wk; SCI: Subcutaneous injection; UP: Ulcerative proctitis; SAZ: Salazopyrin; SI: Sacroiliac; UC: Ulcerative colitis; WNL: Within normal limit.